Drug survival of apremilast in a real‐world setting

M Kishimoto, M Komine, K Kamiya… - The Journal of …, 2019 - Wiley Online Library
Apremilast is a novel oral phosphodiesterase‐4 inhibitor approved for treatment of plaque
psoriasis and psoriatic arthritis in Japan in December 2016. We have treated a substantial …
被引用次数：31 相关文章

Drug survival of apremilast in a real-world setting.

M Kishimoto, M Komine, K Kamiya, J Sugai… - The Journal of …, 2019 - europepmc.org
Apremilast is a novel oral phosphodiesterase-4 inhibitor approved for treatment of plaque
psoriasis and psoriatic arthritis in Japan in December 2016. We have treated a substantial …

Drug survival of apremilast in a real‐world setting

M Kishimoto, M Komine, K Kamiya, J Sugai… - The Journal of …, 2019 - cir.nii.ac.jp
抄録< jats: title> Abstract</jats: title>< jats: p> Apremilast is a novel oral phosphodiesterase‐
4 inhibitor approved for treatment of plaque psoriasis and psoriatic arthritis in Japan in …

Drug survival of apremilast in a real-world setting

M Kishimoto, M Komine, K Kamiya… - The Journal of …, 2019 - pubmed.ncbi.nlm.nih.gov
Apremilast is a novel oral phosphodiesterase-4 inhibitor approved for treatment of plaque
psoriasis and psoriatic arthritis in Japan in December 2016. We have treated a substantial …